ENZC (Enzolytics) ROC %: -323.02% (As of Jun. 2011)


What is Enzolytics ROC %?

Enzolytics ENZC -9.09% ROC % is -323.02% as of Jun. 2011.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Enzolytics's annualized return on capital (ROC %) for the quarter that ended in Jun. 2011 was -323.02%.

As of today (2026-06-25), Enzolytics's WACC % is 0.00%. Enzolytics's ROC % is 0.00% (calculated using TTM income statement data). Enzolytics earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Enzolytics  (OTCPK:ENZC) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Enzolytics's WACC % is 0.00%. Enzolytics's ROC % is 0.00% (calculated using TTM income statement data). Enzolytics earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Enzolytics ROC % Related Terms

Enzolytics ROC % Historical Data

* Premium members only.

The historical data trend for Enzolytics's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enzolytics ROC % Chart

Enzolytics Annual Data
Trend Dec07 Jul08 Dec09 Dec10
ROC %
-33.59 -82.89 -477.04 -846.83

Enzolytics Quarterly Data
Sep07 Dec07 Apr08 Jul08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -314.16 -107.27 -224.02 -300.15 -323.02

Enzolytics ROC % Calculation

Enzolytics's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2010 is calculated as:

ROC % (A: Dec. 2010 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2009 ) + Invested Capital (A: Dec. 2010 ))/ count )
=-2.875 * ( 1 - 0% )/( (0.368 + 0.311)/ 2 )
=-2.875/0.3395
=-846.83 %

where

Invested Capital(A: Dec. 2009 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.085 - 0.982 - ( 0.002 - max(0, 1.274 - 0.009+0.002))
=0.368

Invested Capital(A: Dec. 2010 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.153 - 0.435 - ( 0.001 - max(0, 0.677 - 0.084+0.001))
=0.311

Enzolytics's annualized Return on Capital (ROC %) for the quarter that ended in Jun. 2011 is calculated as:

ROC % (Q: Jun. 2011 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2011 ) + Invested Capital (Q: Jun. 2011 ))/ count )
=-0.856 * ( 1 - 0% )/( (0.35 + 0.18)/ 2 )
=-0.856/0.265
=-323.02 %

where

Invested Capital(Q: Mar. 2011 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.137 - 0.492 - ( 0.009 - max(0, 0.776 - 0.071+0.009))
=0.35

Invested Capital(Q: Jun. 2011 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.112 - 0.661 - ( 0.008 - max(0, 0.778 - 0.049+0.008))
=0.18

Note: The Operating Income data used here is four times the quarterly (Jun. 2011) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of -323.02% mean?
Enzolytics (ENZC) has a ROC % of -323.02% as of Jun. 2011. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Enzolytics and its competitors.
Is Enzolytics' ROC % too high?
Enzolytics' current ROC % is -323.02%.
How does Enzolytics' ROC % compare to competitors?
Enzolytics' ROC % of -323.02% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Biotechnology company?
A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Enzolytics and its competitors. Enzolytics's current ROC % is -323.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enzolytics stock overvalued right now?
Enzolytics (ENZC) has a current ROC % of -323.02%. The current ROC % is -323.02%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Enzolytics (ENZC), the current ROC % is -323.02% as of Jun. 2011. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Enzolytics Business Description

Address 1101 Raintree Circle, Suite 130, Allen, TX, USA, 75013
Enzolytics Inc is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. The company is committed to creating drugs for the good health of mankind. ENZC's flagship compound, ITV-1, is a suspension of Inactivated Pepsin Fragment (IPF), which studies have shown is effective in the treatment of HIV. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system. IPF is a platform technology that can be used to facilitate a broad range of applications. It is free from neurological, gastrointestinal and hematological side effects seen in the anti-retrovirals in use.